Elanco Animal Health
ELAN
22.36
-0.12
-0.53%
Elanco Animal Health
US · ELAN
#1381 by market cap
Listed 2018
22.36
-0.12
-0.53%
Live - 5344 symbols - heartbeat 191s ago
· 2026-10-08 08:30
Pre-market
22.09
-1.21%
After-hours
22.27
-0.40%
- Market cap
- 11.17B
- P/E (TTM)i
- -54.54
- P/Bi
- 1.70
- EPSi
- -0.47
- Div yieldi
- 0.00%
- 52W posi
- 34%
Reader sentiment
Are you bullish or bearish on ELAN?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Mixed / stable
- The number of reporting institutions increased by 1 in the most recent period (2026/Q3).
- Total institutional ownership (as a % of shares) was little changed.
Institutional ownership
- Held by institutions
- 114.23% -0.08pp
- Institutions
- 604 +1
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund102.09%
Hedge Fund6.81%
Public Company2.83%
Government Pension Fund1.04%
Individual/Insider0.71%
Private Company0.70%
Insurance Company0.28%
Family Office/Trust0.25%
Government0.13%
Top holders as of 2026-06-30
Dodge & Cox
13.49% · 67.40M sh
FMR
9.91% · 49.52M sh
BlackRock
9.78% · 48.85M sh
PRIMECAP Management Company
9.10% · 45.45M sh
T. Rowe Price Group, Inc.
6.03% · 30.13M sh
Vanguard Capital Management, LLC
5.16% · 25.77M sh
Dimensional Fund Advisors
5.09% · 25.42M sh
Vanguard Portfolio Management, LLC
4.54% · 22.67M sh
State Street Global Advisors
3.22% · 16.06M sh
Winslow Capital Management, LLC
2.70% · 13.51M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 49 buys · 1 sells
| Name | Role | Stake |
|---|---|---|
| Jeffrey Simmons | Chief Executive Officer | 0.37% |
| Ramiro Cabral | Executive VP & President of Elanco International | 0.04% |
| Ellen de Brabander | Executive Vice President of Innovation, Regulatory & Business Development | 0.04% |
| David Kinard | Executive Vice President of Human Resources, Corporate Communications & Administration | 0.04% |
| Roy Hoover | Independent Chairperson | 0.04% |
| Rajeev Modi | Executive Vice President of U.S. Pet Health & Global Digital Transformation | 0.03% |
| Timothy Bettington | Executive Vice President of Corporate Strategy & Market Development | 0.02% |
| Grace McArdle | Executive Vice President of Manufacturing & Quality | 0.02% |
| Shiv O'Neill | Interim Executive VP, General Counsel & Corporate Secretary | 0.02% |
| Todd Young | Chief Financial Officer | 0.02% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-29 | Kapila Anand | Independent Director | Other Derivative Acquisition | +642 | -- |
| 2026-09-17 | Jeffrey Simmons | Chief Executive Officer | Other Derivative Acquisition | +126 | -- |
| 2026-09-17 | Robert VanHimbergen | Chief Financial Officer | Other Derivative Acquisition | +8 | -- |
| 2026-09-17 | Rajeev Modi | Executive Vice President of U.S. Pet Health & Global Digital Transformation | Other Derivative Acquisition | +65 | -- |
| 2026-09-03 | Jeffrey Simmons | Chief Executive Officer | Other Derivative Acquisition | +115 | -- |
| 2026-09-03 | Robert VanHimbergen | Chief Financial Officer | Other Derivative Acquisition | +8 | -- |
| 2026-09-03 | Rajeev Modi | Executive Vice President of U.S. Pet Health & Global Digital Transformation | Other Derivative Acquisition | +60 | -- |
| 2026-08-20 | Jeffrey Simmons | Chief Executive Officer | Other Derivative Acquisition | +117 | -- |
| 2026-08-20 | Robert VanHimbergen | Chief Financial Officer | Other Derivative Acquisition | +8 | -- |
| 2026-08-20 | Rajeev Modi | Executive Vice President of U.S. Pet Health & Global Digital Transformation | Other Derivative Acquisition | +61 | -- |
| 2026-08-19 | Lawrence Kurzius | Independent Director | Open Market Acquisition | +40,000 | $23.40 |
| 2026-08-17 | Shiv O'Neill | Interim Executive VP, General Counsel & Corporate Secretary | Open Market Acquisition | +3,998 | $23.58 |
| 2026-08-11 | Michael Harrington | Independent Director | Open Market Acquisition | +5,000 | $21.82 |
| 2026-08-06 | Paul Herendeen | Independent Director | Open Market Acquisition | +10,000 | $23.69 |
| 2026-08-06 | Jeffrey Simmons | Chief Executive Officer | Other Derivative Acquisition | +127 | -- |
| 2026-08-06 | Robert VanHimbergen | Chief Financial Officer | Open Market Acquisition | +4,200 | $23.08 |
| 2026-08-06 | Robert VanHimbergen | Chief Financial Officer | Other Derivative Acquisition | +8 | -- |
| 2026-08-06 | Rajeev Modi | Executive Vice President of U.S. Pet Health & Global Digital Transformation | Other Derivative Acquisition | +66 | -- |
| 2026-07-23 | Jeffrey Simmons | Chief Executive Officer | Other Derivative Acquisition | +113 | -- |
| 2026-07-23 | Robert VanHimbergen | Chief Financial Officer | Other Derivative Acquisition | +7 | -- |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 08:30:09 · For reference only, not investment advice and not tailored to your situation.